non-small cell lung cancer

Review

NGS Testing in Non–Small Cell Lung Cancer

09/19/2023

Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...

Winston Wong, PharmD, and Gordon...

09/19/2023

Journal of Clinical Pathways

Videos

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer

07/12/2023

Thomas Stricker , MD;

Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.

Thomas Stricker, MD, PhD, speaks...

07/12/2023

Journal of Clinical Pathways

ASCO Updates Systemic Therapy Guideline for NSCLC With Driver Alterations

03/09/2021

Janelle Bradley ;

The American Society of Clinical Oncology released an update to its guideline on systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations.

The American Society of Clinical...

03/09/2021

Journal of Clinical Pathways

News

Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC

02/15/2021

Journal of Clinical Pathways

News

Timely Specialty Palliative Care for NSCLC Associated With Cost-Savings

12/17/2020

Journal of Clinical Pathways

News

Real-World Outcomes of Companion Diagnostic Testing in Advanced NSCLC

07/09/2020

A new study published in The Oncologist (online July 6, 2020; doi:10.1634/theoncologist.2019-0864) demonstrated the clinical utility of companion diagnostic testing as a first step in treating non-squamous advanced...

A new...

07/09/2020

Journal of Clinical Pathways

News

NCCN Biomarker Guideline Adherence Linked With Decreased Mortality in NSCLC

06/16/2020

Adherence to the National Comprehensive Cancer Network (NCCN) guideline for biomarker testing for non-squamous advanced non-small cell lung cancer (NSCLC) is associated with decreased risk of mortality, according to a recent...

Adherence to the National...

06/16/2020

Journal of Clinical Pathways

News

Real-World Costs of Adverse Events After First-Line Treatment of Metastatic NSCLC

06/09/2020

Real-world patients with metastatic non-small cell lung cancer (NSCLC) who receive first-line immunotherapy are less likely to incur adverse event-related costs than those treated with first-line cytotoxic...

...

06/09/2020

Journal of Clinical Pathways

News

Clinical Pathways Reduce Cost, Increase Clinical Trial Entry for Patients With NSCLC

05/28/2020

A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) demonstrated how standardized evidence-based clinical pathways can be used successfully across a large number of...

A...

05/28/2020

Journal of Clinical Pathways

Research Reports

Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting

02/15/2018

Michael A. Savin , MD;

Ravi Salgia , MD, PhD;

Blase Polite , MD;

Corey Shamah , MD;

Mark A. Socinski , MD;

Amanda Barry , MPH;

Kathy Lokay ;

Peter G. Ellis , MD;

Casey Mason ;

Ray Page , DO, PhD, FACOI, FASCO;

Natalie Dickson , MD;

Abstract: Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non–small cell lung cancer (NSCLC), there...

...

02/15/2018

Journal of Clinical Pathways